Irina Maric

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities
    Irina Maric
    Department of Laboratory Medicine, Clinical Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Allergy Clin Immunol 120:680-7. 2007
  2. doi request reprint Bone marrow findings in HIV-positive patients with Kaposi sarcoma herpesvirus-associated multicentric Castleman disease
    Girish Venkataraman
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Am J Clin Pathol 139:651-61. 2013
  3. pmc B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute NCI, Bethesda, MD 20892, USA
    Blood 119:2709-20. 2012
  4. pmc mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells
    Daniel Smrz
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1881, USA
    Blood 118:6803-13. 2011
  5. pmc Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases
    Prashant R Tembhare
    Flow Cytometry Laboratory, Laboratory of Pathology, CCR, NCI, NIH, Bethesda, MD, USA
    Leuk Res 38:371-6. 2014
  6. pmc KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells
    Eunice Ching Chan
    Mast Cell Biology Section, Laboratory of Allergic Diseases, Bethesda, MD, USA
    Exp Hematol 41:870-881.e2. 2013
  7. pmc IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis
    Todd M Wilson
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
    J Allergy Clin Immunol 128:1086-92.e1-3. 2011
  8. pmc Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Blood 110:3552-6. 2007
  9. pmc MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response
    Weixin Wang
    Department of Laboratory Medicine, Hematology Section NIH Clinical Center, 10 Center Dr, Bldg 10 2C306 Bethesda, 20892 1508, USA
    Haematologica 97:586-94. 2012
  10. pmc Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis
    Todd M Wilson
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 20892 1881, USA
    Haematologica 96:459-63. 2011

Detail Information

Publications28

  1. ncbi request reprint KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities
    Irina Maric
    Department of Laboratory Medicine, Clinical Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Allergy Clin Immunol 120:680-7. 2007
    ..It is of paramount importance, however, to distinguish between these 2 groups of patients because of differences in clinical sequelae, prognoses, and selection of treatment...
  2. doi request reprint Bone marrow findings in HIV-positive patients with Kaposi sarcoma herpesvirus-associated multicentric Castleman disease
    Girish Venkataraman
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Am J Clin Pathol 139:651-61. 2013
    ..Bone marrow biopsy specimens in KSHV-MCD patients recapitulate findings of interleukin-6 excess. In patients with HIV, unexplained cytopenias, and bone marrow plasmacytosis, evaluation for KSHV-MCD is warranted...
  3. pmc B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute NCI, Bethesda, MD 20892, USA
    Blood 119:2709-20. 2012
    ....
  4. pmc mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells
    Daniel Smrz
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1881, USA
    Blood 118:6803-13. 2011
    ....
  5. pmc Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases
    Prashant R Tembhare
    Flow Cytometry Laboratory, Laboratory of Pathology, CCR, NCI, NIH, Bethesda, MD, USA
    Leuk Res 38:371-6. 2014
    ..We evaluated differences in antigen expression patterns among MGUS (N = 14), SMM (N = 35) and MM (N = 10), finding the combination of CD45 and CD56 helpful in differentiating MGUS from SMM and MM (p = 0.0002)...
  6. pmc KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells
    Eunice Ching Chan
    Mast Cell Biology Section, Laboratory of Allergic Diseases, Bethesda, MD, USA
    Exp Hematol 41:870-881.e2. 2013
    ..These data suggest that neoplastic mast cells favor a GNNK(-) variant predominance, which in turn enhances the activating potential of the KIT D816V mutation and thus could influence therapeutic sensitivity in systemic mastocytosis. ..
  7. pmc IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis
    Todd M Wilson
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
    J Allergy Clin Immunol 128:1086-92.e1-3. 2011
    ..Although IL-5, IL-3, and GM-CSF can modulate the expression of IL-5 receptor α (IL-5Rα) on eosinophils in vitro, little is known about soluble and surface IL-5Rα levels in vivo...
  8. pmc Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing
    Amy D Klion
    Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Blood 110:3552-6. 2007
    ..This trial was registered at http://www.clinicaltrials.gov as no. NCT00044304...
  9. pmc MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response
    Weixin Wang
    Department of Laboratory Medicine, Hematology Section NIH Clinical Center, 10 Center Dr, Bldg 10 2C306 Bethesda, 20892 1508, USA
    Haematologica 97:586-94. 2012
    ..MicroRNAs can play an important role in tumorigenesis through post-transcriptional regulation of gene expression, and are not well characterized in follicular lymphoma...
  10. pmc Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis
    Todd M Wilson
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 20892 1881, USA
    Haematologica 96:459-63. 2011
    ..Unlike other mature lineages, mast cell survival is dependent on KIT and the presence of these two activating mutations may have a greater impact on the expansion of this cell compartment and in resultant disease severity...
  11. pmc Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
    Patricia Perez-Galan
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 117:542-52. 2011
    ..Expression of CD38 and IRF4 could serve as markers of bortezomib resistance in MCL. This study has been registered at http://clinicaltrials.gov as NCT00131976...
  12. pmc Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications
    Katherine R Calvo
    Hematology Section, Department of Laboratory Medicine, NIH Clinical Center, 10 Center Dr, Bethesda, MD 20892 1508, USA
    Haematologica 96:1221-5. 2011
    ..MonoMAC appears to be a unique, inherited syndrome of bone marrow failure. We describe distinctive bone marrow features to help in its recognition and diagnosis. (Clinicaltrials.gov identifiers: NCT00018044, NCT00923364, NCT01212055)...
  13. ncbi request reprint Prospective cell sorting of embryonic rat neural stem cells and neuronal and glial progenitors reveals selective effects of basic fibroblast growth factor and epidermal growth factor on self-renewal and differentiation
    Dragan Maric
    Laboratory of Neurophysiology, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Neurosci 23:240-51. 2003
    ....
  14. pmc Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review
    Jane A Little
    Vascular Medicine Branch, National Heart Lung and Blood Institute, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1476, USA
    Haematologica 91:1076-83. 2006
    ..Furthermore EPO appears to be safe in SCD, particularly when used in conjunction with HU. We outline our current therapeutic strategy for EPO use in SCD...
  15. pmc Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p
    Meral Gunay-Aygun
    Section on Human Biochemical Genetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 116:4990-5001. 2010
    ..This study is registered at www.clinicaltrials.gov as NCT00069680 and NCT00369421...
  16. ncbi request reprint Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study
    Benjamin M Cherry
    Multiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Leuk Lymphoma 54:2215-8. 2013
    ..0001), low versus non-low (p = 0.0007) and high versus non-high (p < 0.0001) risk. There is a need for prospectively validated models to characterize individual patient risk of transformation to MM...
  17. pmc Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na
    Matthew J Olnes
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Leuk Res 36:982-9. 2012
    ..Knockdown" of cyclin D1 by RNA interference decreased trisomy 8 cell growth, suggesting that this might be a therapeutic target in MDS...
  18. pmc Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
    James N Kochenderfer
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 116:4099-102. 2010
    ..Adoptive transfer of anti-CD19-CAR-expressing T cells is a promising new approach for treating B-cell malignancies. This study is registered at www.clinicaltrials.gov as #NCT00924326...
  19. pmc Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency
    Robert Sokolic
    Disorders of Immunity Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, Bethesda, MD 20892, USA
    Blood 118:2688-94. 2011
    ..These trials were registered at www.clinicaltrials.gov as #NCT00018018 and #NCT00006319...
  20. pmc Pediatric-onset mastocytosis: a long term clinical follow-up and correlation with bone marrow histopathology
    Ashraf Uzzaman
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Pediatr Blood Cancer 53:629-34. 2009
    ..We addressed the long term prognosis of pediatric-onset disease by examining 17 children with mastocytosis which we had reported on in 1989 [1]...
  21. ncbi request reprint The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders
    Fanny Legrand
    Eosinophil Pathology Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Md Electronic address
    J Allergy Clin Immunol 133:1439-47, 1447.e1-8. 2014
    ..Although several novel agents are currently in clinical trials for eosinophilic disorders, none has demonstrated efficacy in reducing blood and tissue eosinophilia in all subjects. Additional approaches are clearly needed...
  22. pmc An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease
    Thomas S Uldrick
    HIV and AIDS Malignancy Branch, National Cancer Institute Frederick, Frederick, MD, USA
    Clin Infect Dis 51:350-8. 2010
    ..Patients with KSHV-MCD develop fevers, wasting, hypoalbuminemia, cytopenias, and hyponatremia that are related to overproduction of KSHV-encoded viral interleukin (IL)-6 (vIL-6) and human IL-6 (hIL-6)...
  23. pmc Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy
    Claude Sportes
    Experimental Transplantation and Immunology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1203, USA
    Clin Cancer Res 16:727-35. 2010
    ..We report here on the toxicity and biological activity of recombinant human IL-7 (rhIL-7) in humans...
  24. pmc Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy
    Jane A Little
    Pulmonary and Vascular Medicine Branch, National Heart Lung and Blood Institute, NIH, Bethesda, MD 20892 1476, USA
    Eur J Haematol 82:315-21. 2009
    ..L-arginine, an NO precursor, and the phosphodiesterase (PDE) 5 inhibitor sildenafil, which potentiates cGMP, were studied in adults with sickle cell disease (SCD) who were stably on HU...
  25. pmc The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia
    Yair Herishanu
    National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 117:563-74. 2011
    ..These data identify the disruption of tumor microenvironment interactions and the inhibition of BCR signaling as promising therapeutic strategies in CLL. This study is registered at http://clinicaltrials.gov as NCT00019370...
  26. pmc von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells
    Deric M Park
    Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Med 4:e60. 2007
    ....
  27. doi request reprint Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion
    Idoya Lahortiga
    Human Genome Laboratory, Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium
    Haematologica 93:49-56. 2008
    ..We report an unusual case of a patient presenting with peripheral basophilia and systemic mastocytosis in whom cytogenetic analysis revealed a t(4;5)(q21.1;q31.3)...
  28. pmc Selective generation of functional somatically mutated IgM+CD27+, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease
    Cindy S Ma
    Lymphocyte Differentiation Laboratory, Centenary Institute of Cancer Medicine and Cell Biology, Newtown, New South Wales, Australia
    J Clin Invest 116:322-33. 2006
    ..Production of affinity-matured IgM by IgMCD27 B cells may protect against pathogens to which a normal immune response is elicited in XLP patients...